globe usa magnifying-glass checkbox g-plus rss youtube fb-round connect-with-us-in connect-with-us-twitter youtube2 facebook linkedin twitter
The website you have requested may contain information on products or uses of such products that are not approved in your country. For specific product and country information please contact Medinol

The Iberian Registry

  • Multi-center, post-market surveillance registry evaluating the performance and long term safety of the NIRxcell stent
  • 318 patients enrolled in Spain and Portugal
  • De novo native coronary artery lesions
  • Primary endpoint: composite of MACE (cardiac death, MI and clinically-driven TLR) at 12 months
  • Result: MACE at 12 months was 2.9% (significantly lower than the performance goal of 15.0%) and clinically-driven TLR rate at 12 months was 1.6%